About Us  |  Contact Us  |  Español
Butler Hospital
Butler Hospital

Organizations Butler
Research Type Clinical
Therapeutic Area of Study Alzheimer's disease
Principal Investigators Stephen Salloway MD, MS
Related Publications
Eligibility Criteria This study is being conducted in men and women aged 50 to 90 years old.  Apart from the clinical AD diagnosis, patients must be in good health as determined by the physician, based on medical history and the screening assessments.
Recruitment Status Closed
Contact Information

memory@butler.org

Description

This is a Phase 1b study researching an amyloid antibody drug, labeled BIIB037, as a potential treatment for patients with prodromal or mild Alzheimer's Disease, AD. Patients receive the drug or placebo through an IV in their arm once every 4 weeks for the first year. There is an optional second year of treatment in which the patient will be guaranteed to receive the study drug (no placebo).

Look for another study
Health Headlines
FDA Approves Another Weekly Injectable Drug for Type 2 DiabetesView in a lightbox
Trulicity Approved for Type 2 DiabetesView in a lightbox
U.S. Gun Deaths Lowest in Hawaii, Highest in D.C.View in a lightbox
More Schools Stocking Shots That Counter Serious Allergic ReactionsView in a lightbox
Some U.S. Troops May Face Greater Skin Cancer RiskView in a lightbox
Butler Hospital
© 2011 Site Index | Disclaimer | Legal Notices | Talks Your Health